Trial Profile
Phase I study of CFAK-C4 + gemcitabine in patients with pancreatic cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2011
Price :
$35
*
At a glance
- Drugs CFAK C4 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 19 Jan 2011 CureFAKtor Pharmaceuticals have received Orphan Drug Designation for CFAK-C4 for the treatment of pancreatic cancer, according to a CureFAKtor media release
- 19 Jan 2011 The study will be initiated in 2012, according to a CureFAKtor Pharmaceuticals media release
- 19 Jan 2011 New trial record